

## DORSET MEDICINES ADVISORY GROUP Recommendation Summary

Formerly the Bournemouth, Dorset and Poole Health Technologies Forum, DMAG represents the four provider Trusts and GPs within the Clinical Commissioning Group (CCG). It provides recommendations to the CCG on the prescribing and commissioning of medicines.

Summary of recommendations considered at a meeting of the group on 12<sup>th</sup> July 2016. Formulary entries and associated documents can be accessed at [www.dorsetformulary.nhs.uk](http://www.dorsetformulary.nhs.uk).

PRODUCT	DECISION	COMMENTS
<b>1. Products re-categorised</b>		
No proposals for re-categorisation noted		
<b>2. New requests</b>		
Otovent®	Not approved	The decision is not to include Otovent® on the pan Dorset Formulary as it is classified as a device.
<b>3. Products considered by NICE</b>		
Commissioning statement on the use of Evolocumab and Alirocumab	Approved	In accordance with NICE Technology Appraisals 393 and 394 . <a href="#">See commissioning statement here</a>
Commissioning statement on the use of SGLT2s as monotherapy	Approved	In accordance with NICE Technology Appraisal 390 <a href="#">See commissioning statement here</a>

PRODUCT	DECISION	COMMENTS
<b>4. Miscellaneous recommendations by DMAG</b>		
Direct Oral Anticoagulant (DOAC) Alert Care	Approved	This is now available as an electronic document on both the CCG website and pan Dorset Formulary
Urticaria Pathway	Approved	This is now available on both the CCG website and pan Dorset Formulary
Shared care guidelines for the use of ACH inhibitors and Memantine in Alzheimer's disease	Approved	This is now available on both the CCG website and pan Dorset Formulary
Commissioning statement on the use of Plenadren®	Approved	This is now available on both the CCG website and pan Dorset Formulary
Commissioning statement on the combined use of a GLP-1 agent with insulin	Approved	This is now available on both the CCG website and pan Dorset Formulary
The reduction in the threshold for the initiation of Toujeo®	Approved	The threshold of 200 units basal insulin daily dose reduced .Formulary now reflects the following: For use in patients requiring a basal daily dose of between 100 – 160 units.

Classification of products:

'RED' drugs for hospital use only

'AMBER with shared care' drugs suitable for use with shared care arrangements

'AMBER' drugs suitable for use without shared care arrangements

'GREEN' drugs suitable for prescribing in primary and secondary care

'Not Recommended' – drugs not recommended for use in Dorset

The new traffic light system can be found on the Dorset CCG internet at: [Dorset CCG - Traffic light scheme](#)